Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.08
BASI's Cash-to-Debt is ranked lower than
93% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. BASI: 0.08 )
Ranked among companies with meaningful Cash-to-Debt only.
BASI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: N/A
Current: 0.08
Equity-to-Asset 0.38
BASI's Equity-to-Asset is ranked lower than
79% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. BASI: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
BASI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.43 Max: 0.83
Current: 0.38
0.31
0.83
Piotroski F-Score: 3
Altman Z-Score: -0.09
Beneish M-Score: -3.62
WACC vs ROIC
6.79%
-12.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -7.04
BASI's Operating Margin % is ranked lower than
56% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. BASI: -7.04 )
Ranked among companies with meaningful Operating Margin % only.
BASI' s Operating Margin % Range Over the Past 10 Years
Min: -20.16  Med: 2.56 Max: 6.7
Current: -7.04
-20.16
6.7
Net Margin % -8.95
BASI's Net Margin % is ranked lower than
56% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. BASI: -8.95 )
Ranked among companies with meaningful Net Margin % only.
BASI' s Net Margin % Range Over the Past 10 Years
Min: -22.39  Med: -3.96 Max: 6.95
Current: -8.95
-22.39
6.95
ROE % -24.08
BASI's ROE % is ranked lower than
61% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.56 vs. BASI: -24.08 )
Ranked among companies with meaningful ROE % only.
BASI' s ROE % Range Over the Past 10 Years
Min: -55.71  Med: -9.73 Max: 18.44
Current: -24.08
-55.71
18.44
ROA % -9.27
BASI's ROA % is ranked lower than
54% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. BASI: -9.27 )
Ranked among companies with meaningful ROA % only.
BASI' s ROA % Range Over the Past 10 Years
Min: -21.3  Med: -3.97 Max: 7.42
Current: -9.27
-21.3
7.42
ROC (Joel Greenblatt) % -9.88
BASI's ROC (Joel Greenblatt) % is ranked lower than
53% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.92 vs. BASI: -9.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BASI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -28.7  Med: 2.3 Max: 15.35
Current: -9.88
-28.7
15.35
3-Year Revenue Growth Rate -1.50
BASI's 3-Year Revenue Growth Rate is ranked lower than
67% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. BASI: -1.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BASI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -23.4  Med: -1.2 Max: 14.9
Current: -1.5
-23.4
14.9
GuruFocus has detected 5 Warning Signs with Bioanalytical Systems Inc $BASI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BASI's 30-Y Financials

Financials (Next Earnings Date: 2017-08-11 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325412    SIC: 2834
Compare:OTCPK:CRRVF, OTCPK:MDIT, OTCPK:ILIU, OTCPK:LEDIF, NAS:ROKA, NAS:GENE, NAS:CBMX, OTCPK:MNLIF, OTCPK:MYAN, OTCPK:EXDI, NAS:IDXG, OTCPK:GNWSF, NAS:TEAR, OTCBB:RPBIF, OTCPK:LXXGF, OTCPK:MHTX, OTCPK:MTST, OTCPK:TBIOD, NAS:OPGN, OTCPK:TDSGF » details
Traded in other countries:BS5.Germany,
Headquarter Location:USA
Bioanalytical Systems Inc is a contract research organization providing drug discovery and development services and analytical instruments. Its customers and partners include pharmaceutical, biotechnology, academic and government organizations.

Bioanalytical Systems Inc is a corporation organized in Indiana in 1974. The Company is a contract research organization providing drug discovery and development services and analytical instruments. Its clients and partners include pharmaceutical, biotechnology, academic and government organizations. It supports the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. The Companys principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research from small start-up biotechnology companies to many of the largest global pharmaceutical companies. The drug discovery and development process is heavily regulated by the FDA and its Center for Drug Evaluation and Research. It operates in two business segments contract research services and research products, both of which address the bioanalytical, preclinical, and clinical research needs of drug developers. The contract research services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance and quality control testing. The services provided by its contract research services segment include Product Characterization, Method Development and Validation, Bioanalytical Testing, Stability Testing, In Vivo Pharmacology, and Preclinical and Pathology Services. The products business targets life science research and designs, develops, manufactures and markets Analytical Products, In vivo Sampling Products, Vetronics Products. It promotes its services through concentrated business development efforts, scientist-to-scientist communications and centralized corporate marketing programs. The Company competes with in-house research, development, quality control and other support service departments of pharmaceutical and biotechnology companies. Its competitors include Covance, Inc., Pharmaceutical Product Development, Inc., Charles River Laboratories, Inc., Quintiles Transnational Holdings, Inc. The Company is subject to various regulatory requirements designed to ensure the quality and integrity of its data and products.

Ratios

vs
industry
vs
history
PB Ratio 1.88
BASI's PB Ratio is ranked higher than
82% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. BASI: 1.88 )
Ranked among companies with meaningful PB Ratio only.
BASI' s PB Ratio Range Over the Past 10 Years
Min: 0.23  Med: 1.32 Max: 3.22
Current: 1.88
0.23
3.22
PS Ratio 0.60
BASI's PS Ratio is ranked higher than
93% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. BASI: 0.60 )
Ranked among companies with meaningful PS Ratio only.
BASI' s PS Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.47 Max: 1.14
Current: 0.6
0.1
1.14
Price-to-Free-Cash-Flow 18.93
BASI's Price-to-Free-Cash-Flow is ranked higher than
66% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. BASI: 18.93 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BASI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.39  Med: 12.55 Max: 213.75
Current: 18.93
1.39
213.75
Price-to-Operating-Cash-Flow 8.82
BASI's Price-to-Operating-Cash-Flow is ranked higher than
91% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.63 vs. BASI: 8.82 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BASI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.24  Med: 7.43 Max: 42.07
Current: 8.82
1.24
42.07
EV-to-EBITDA 119.82
BASI's EV-to-EBITDA is ranked lower than
94% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.45 vs. BASI: 119.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
BASI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -77.1  Med: 8.8 Max: 131.3
Current: 119.82
-77.1
131.3
Current Ratio 0.41
BASI's Current Ratio is ranked lower than
96% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. BASI: 0.41 )
Ranked among companies with meaningful Current Ratio only.
BASI' s Current Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.03 Max: 3.95
Current: 0.41
0.35
3.95
Quick Ratio 0.32
BASI's Quick Ratio is ranked lower than
96% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. BASI: 0.32 )
Ranked among companies with meaningful Quick Ratio only.
BASI' s Quick Ratio Range Over the Past 10 Years
Min: 0.24  Med: 0.8 Max: 3.05
Current: 0.32
0.24
3.05
Days Inventory 29.84
BASI's Days Inventory is ranked higher than
72% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.10 vs. BASI: 29.84 )
Ranked among companies with meaningful Days Inventory only.
BASI' s Days Inventory Range Over the Past 10 Years
Min: 22.9  Med: 30.19 Max: 36.89
Current: 29.84
22.9
36.89
Days Sales Outstanding 43.67
BASI's Days Sales Outstanding is ranked higher than
76% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.30 vs. BASI: 43.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
BASI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.44  Med: 46.62 Max: 81.92
Current: 43.67
29.44
81.92
Days Payable 39.38
BASI's Days Payable is ranked lower than
67% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.24 vs. BASI: 39.38 )
Ranked among companies with meaningful Days Payable only.
BASI' s Days Payable Range Over the Past 10 Years
Min: 18.44  Med: 37.15 Max: 87.14
Current: 39.38
18.44
87.14

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.70
BASI's 3-Year Average Share Buyback Ratio is ranked higher than
70% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. BASI: -1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BASI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.1  Med: -1.7 Max: -0.1
Current: -1.7
-16.1
-0.1

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 1.89
BASI's Price-to-Tangible-Book is ranked higher than
87% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.16 vs. BASI: 1.89 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BASI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.33  Med: 1.5 Max: 3.33
Current: 1.89
0.33
3.33
Price-to-Intrinsic-Value-Projected-FCF 1.81
BASI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
60% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. BASI: 1.81 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BASI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.28  Med: 0.96 Max: 63
Current: 1.81
0.28
63
Price-to-Median-PS-Value 1.25
BASI's Price-to-Median-PS-Value is ranked lower than
67% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. BASI: 1.25 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BASI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 1.28 Max: 4.19
Current: 1.25
0.28
4.19
Earnings Yield (Greenblatt) % -8.41
BASI's Earnings Yield (Greenblatt) % is ranked lower than
64% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. BASI: -8.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BASI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -33.5  Med: -2.3 Max: 18
Current: -8.41
-33.5
18
Forward Rate of Return (Yacktman) % -2.50
BASI's Forward Rate of Return (Yacktman) % is ranked lower than
77% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.56 vs. BASI: -2.50 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BASI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -12.1  Med: 7 Max: 34.5
Current: -2.5
-12.1
34.5

More Statistics

Revenue (TTM) (Mil) $22.74
EPS (TTM) $ -0.25
Beta0.71
Short Percentage of Float1.51%
52-Week Range $0.60 - 2.42
Shares Outstanding (Mil)8.19
» More Articles for BASI

Headlines

Articles On GuruFocus.com
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 09 2011 
Bioanalytical Systems Inc. Reports Operating Results (10-Q/A) May 20 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) May 17 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 16 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-K/A) Feb 10 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Aug 12 2009 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) May 18 2009 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 23 2009 

More From Other Websites
BASi Announces Validated "SEND" Capabilities and Compliance With FDA's Standard for Exchange of... Jun 07 2017
Bioanalytical Systems, Inc. :BASI-US: Earnings Analysis: Q2, 2017 By the Numbers : May 24, 2017 May 24 2017
BASi Reports Second Quarter Results May 15 2017
Bioanalytical Systems to Release Second Quarter Fiscal 2017 Results on Monday, May 15, 2017 May 10 2017
BASi Announces Appointment of Scientific Advisor May 01 2017
Bioanalytical Systems, Inc. :BASI-US: Earnings Analysis: Q1, 2017 By the Numbers : March 16, 2017 Mar 16 2017
BASi Names Philip A. Downing Senior Vice President of Preclinical Services Mar 08 2017
BASi Reports First Quarter Results Feb 14 2017
Bioanalytical Systems to Release First Quarter Fiscal 2017 Results on Tuesday, February 14, 2017 Feb 13 2017
Bioanalytical Systems, Inc. :BASI-US: Earnings Analysis: Q4, 2016 By the Numbers : January 17, 2017 Jan 17 2017
BASi Reports Fiscal 2016 Full Year and Fourth Quarter Results Dec 22 2016
BASi Names Alan Loch Director of Business Development Dec 20 2016
CORRECTING and REPLACING Bioanalytical Systems to Release Fiscal 2016 Results on Thursday, December... Dec 20 2016
Bioanalytical (BASI) Launches Sampling System, Stock Down Aug 26 2016
BASi Launches Embrace Automation Grant Program with Culex NxT™ Automated Blood Sampling System Aug 25 2016
Bioanalytical Systems, Inc. :BASI-US: Earnings Analysis: Q3, 2016 By the Numbers : August 15, 2016 Aug 15 2016
BASi Reports Third Quarter Results Aug 11 2016
Bioanalytical Systems to Release Third Quarter Fiscal 2016 Results on Thursday, August 11, 2016;... Aug 03 2016
BASi Expands Electrochemical Offerings by Partnering with PalmSens BV Jul 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}